Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Rating of “Moderate Buy” from Analysts

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $13.80.

Several equities analysts have recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of Orchestra BioMed in a research report on Thursday, March 12th. Barclays boosted their price objective on Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Wall Street Zen upgraded Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, TD Cowen assumed coverage on Orchestra BioMed in a research report on Wednesday, December 10th. They issued a “buy” rating for the company.

Insider Transactions at Orchestra BioMed

In other news, insider David P. Hochman acquired 10,000 shares of Orchestra BioMed stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the purchase, the insider directly owned 1,086,467 shares of the company’s stock, valued at $4,660,943.43. This trade represents a 0.93% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 8.10% of the stock is owned by company insiders.

Institutional Trading of Orchestra BioMed

A number of institutional investors and hedge funds have recently modified their holdings of OBIO. China Universal Asset Management Co. Ltd. bought a new position in shares of Orchestra BioMed in the 4th quarter worth about $38,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Orchestra BioMed in the 2nd quarter valued at about $31,000. Virtu Financial LLC bought a new stake in shares of Orchestra BioMed during the 4th quarter valued at about $57,000. Creative Planning bought a new stake in shares of Orchestra BioMed during the 2nd quarter valued at about $40,000. Finally, XTX Topco Ltd acquired a new stake in Orchestra BioMed during the second quarter worth about $45,000. 53.20% of the stock is owned by institutional investors and hedge funds.

Orchestra BioMed Trading Down 2.2%

OBIO opened at $4.51 on Thursday. Orchestra BioMed has a 12-month low of $2.20 and a 12-month high of $5.42. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.45 and a quick ratio of 6.43. The stock has a market capitalization of $263.93 million, a PE ratio of -3.99 and a beta of 0.56. The firm’s fifty day moving average price is $4.19 and its 200 day moving average price is $3.89.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.64. The company had revenue of $30.92 million during the quarter, compared to analyst estimates of $0.93 million. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. As a group, research analysts expect that Orchestra BioMed will post -1.66 EPS for the current fiscal year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.